Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This letter comments on Wei 's study applying the Wave-Vision Transformer for oesophageal cancer classification. Highlighting its superior accuracy and efficiency, we discuss its potential clinical impact, limitations in dataset diversity, and the need for explainable artificial intelligence to enhance adoption in pathology and personalized treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400239 | PMC |
| http://dx.doi.org/10.5306/wjco.v16.i8.109893 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Segmental analysis of esophageal and gastric fundus microbiome diversity in reflux esophagitis.
Folia Microbiol (Praha)
September 2025
Department of Gastroenterology, Chongqing University Cancer Hospital, Chongqing, China.
Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.
View Article and Find Full Text PDFImpact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study.
Cancer Immunol Immunother
September 2025
Guangdong Provincial Clinical Research Center for Cancer, State Key Laboratory of Oncology in South China, Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangdong Esophageal Cancer Institute, Guangzhou, 510060, China.
Background: Previous studies indicated that over-dissection of lymph nodes might impair the efficacy of immunotherapy. This study aims to explore the prognostic value of ypN + status and the impact of lymph node dissection (LND) on survival after neoadjuvant immunochemotherapy (NICT) for esophageal squamous cell cancer (ESCC).
Methods: This double-center retrospective study enrolled 206 consecutive ESCC patients who underwent NICT followed by esophagectomy between 2018 and 2024.
Clinical features of Barrett's mucosa arising in the remnant esophagus after subtotal esophagectomy and esophago-gastric anastomosis for esophageal cancer.
Esophagus
September 2025
Department of Upper Gastrointestinal Surgery, Dokkyo Medical University, 880 Kitakobayashi, Mibu, Shimotsugagun, Tochigi, 321-0293, Japan.
Background: Barrett's mucosa in the remnant esophagus (BMRE) is often identified after gastric pull-up reconstruction after esophagectomy. This study aimed to determine the clinical characteristics of BMRE and the factors that affect the development of BMRE.
Methods: The characteristics of BMRE and factors affecting its occurrence were studied in patients with subtotal esophagectomy and gastric pull-up reconstruction who survived at least 3 years after esophageal cancer surgery and who were evaluated by endoscopy.
Artificial intelligence in medical imaging empowers precision neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
J Immunother Cancer
September 2025
CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, China
Neoadjuvant immunochemotherapy (nICT) has demonstrated significant potential in improving pathological response rates and survival outcomes for patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, substantial interindividual variability in therapeutic outcomes highlights the urgent need for more precise predictive tools to guide clinical decision-making. Traditional biomarkers remain limited in both predictive performance and clinical feasibility.
View Article and Find Full Text PDFTreat the Tumor, Spare the Esophagus: The Case for Organ Preservation in Locally Advanced Esophageal/Gastroesophageal Junction Cancer.
J Clin Oncol
September 2025
Division of Hematology and Medical Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.